BioCentury
ARTICLE | Clinical News

15-HEPE: Phase I data

January 4, 2016 8:00 AM UTC

A double-blind, placebo-controlled Phase I trial in 56 healthy volunteers showed that single and multiple doses of oral DS102 for 28 days were well tolerated with no serious adverse events or disconti...